IOBT

IO Biotech (IOBT)

About IO Biotech (IOBT)

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

Details

Daily high

$0.99

Daily low

$0.87

Price at open

$0.90

52 Week High

$1.89

52 Week Low

$0.66

Market cap

62.3M

Dividend yield

0.00%

Volume

230,965

Avg. volume

146,445

P/E ratio

-.69

IO Biotech News